Patent Grant
11612385
This application generally relates to devices and methods for delivering implantable devices to the atrial septum, particularly in subjects with heart pathologies such as pulmonary arterial hypertension (PAH), congestive heart failure (CHF) or myocardial infarction (MI).
Pulmonary arterial hypertension occurs when the pressure within the blood vessels and lungs becomes too high. PAH may be caused by obstruction in the arties in the lung such as the development of scar tissue in the blood vessels of the lungs, but in many cases, the cause is unknown. Under normal conditions, the pressure within the right side of the heart and the blood vessels of the lungs is lower than the rest of the body which maximizes oxygenation of the blood in the lungs. With PAH, the heart must work harder under greater pressure to pump blood through the arteries in the lungs, weakening the heart muscles over time. As a result, the heart may be unable to sufficiently pump blood to the lungs to be oxygenated to keep the body functioning normally.
Heart failure is the physiological state in which cardiac output is insufficient to meet the needs of the body or to do so only at a higher filling pressure. There are many underlying causes of HF, including myocardial infarction, coronary artery disease, valvular disease, hypertension, and myocarditis. Chronic heart failure is associated with neurohormonal activation and alterations in autonomic control. Although these compensatory neurohormonal mechanisms provide valuable support for the heart under normal physiological circumstances, they also play a fundamental role in the development and subsequent progression of HF.
For example, one of the body's main compensatory mechanisms for reduced blood flow in HF is to increase the amount of salt and water retained by the kidneys. Retaining salt and water, instead of excreting it via urine, increases the volume of blood in the bloodstream and helps to maintain blood pressure. However, the larger volumes of blood also cause the heart muscle, particularly the ventricles, to become enlarged. As the heart chambers become enlarged, the wall thickness decreases and the heart's contractions weaken, causing a downward spiral in cardiac function. Another compensatory mechanism is vasoconstriction of the arterial system, which raises the blood pressure to help maintain adequate perfusion, thus increasing the load that the heart must pump against.
In low ejection fraction (EF) heart failure, high pressures in the heart result from the body's attempt to maintain the high pressures needed for adequate peripheral perfusion. However, as the heart weakens as a result of such high pressures, the disorder becomes exacerbated. Pressure in the left atrium may exceed 25 mmHg, at which stage fluids from the blood flowing through the pulmonary circulatory system transudate or flow out of the pulmonary capillaries into the pulmonary interstitial spaces and into the alveoli, causing lung congestion and, if untreated, the syndrome of acute pulmonary edema and death.
Table 1 lists typical ranges of right atrial pressure (RAP), right ventricular pressure (RVP), left atrial pressure (LAP), left ventricular pressure (LVP), cardiac output (CO), and stroke volume (SV) for a normal heart and for a heart suffering from HF. In a normal heart beating at around 70 beats/minute, the stroke volume needed to maintain normal cardiac output is about 60 to 100 milliliters. When the preload, after-load, and contractility of the heart are normal, the pressures required to achieve normal cardiac output are listed in Table 1. In a heart suffering from HF, the hemodynamic parameters change (as shown in Table 1) to maintain peripheral perfusion.
HF is generally classified as either systolic heart failure (SHF) or diastolic heart failure (DHF). In SHF, the pumping action of the heart is reduced or weakened. A common clinical measurement is the ejection fraction, which is a function of the blood ejected out of the left ventricle (stroke volume) divided by the maximum volume in the left ventricle at the end of diastole or relaxation phase. A normal ejection fraction is greater than 50%. Systolic heart failure generally causes a decreased ejection fraction of less than 40%. Such patients have heart failure with reduced ejection fraction (HFrEF). A patient with HFrEF may usually have a larger left ventricle because of a phenomenon called “cardiac remodeling” that occurs secondary to the higher ventricular pressures.
In DHF, the heart generally contracts normally, with a normal ejection fraction, but is stiffer, or less compliant, than a healthy heart would be when relaxing and filling with blood. Such patients are said to have heart failure with preserved ejection fraction (HFpEF). This stiffness may impede blood from filling the heart and produce backup into the lungs, which may result in pulmonary venous hypertension and lung edema. HFpEF is more common in patients older than 75 years, especially in women with high blood pressure.
Both variants of HF have been treated using pharmacological approaches, which typically involve the use of vasodilators for reducing the workload of the heart by reducing systemic vascular resistance, as well as diuretics, which inhibit fluid accumulation and edema formation, and reduce cardiac filling pressure. No pharmacological therapies have been shown to improve morbidity or mortality in HFpEF whereas several classes of drugs have made an important impact on the management of patients with HFrEF, including renin-angiotensin antagonists, beta blockers, and mineralocorticoid antagonists. Nonetheless, in general, HF remains a progressive disease and most patients have deteriorating cardiac function and symptoms over time. In the U.S., there are over 1 million hospitalizations annually for acutely worsening HF and mortality is higher than for most forms of cancer.
In more severe cases of HFrEF, assist devices such as mechanical pumps are used to reduce the load on the heart by performing all or part of the pumping function normally done by the heart. Chronic left ventricular assist devices (LVAD), and cardiac transplantation, often are used as measures of last resort. However, such assist devices typically are intended to improve the pumping capacity of the heart, to increase cardiac output to levels compatible with normal life, and to sustain the patient until a donor heart for transplantation becomes available. Such mechanical devices enable propulsion of significant volumes of blood (liters/min), but are limited by a need for a power supply, relatively large pumps, and pose a risk of hemolysis, thrombus formation, and infection. Temporary assist devices, intra-aortic balloons, and pacing devices have also been used.
Various devices have been developed using stents to modify blood pressure and flow within a given vessel, or between chambers of the heart. Implantable interatrial shunt devices have been successfully used in patients with severe symptomatic heart failure. By diverting or shunting blood from the left atrium (LA) to the right atrium (RA), the pressure in the left atrium is lowered or prevented from elevating as high as it would otherwise (left atrial decompression). Such an accomplishment would be expected to prevent, relieve, or limit the symptoms, signs, and syndromes associated of pulmonary congestion. These include severe shortness of breath, pulmonary edema, hypoxia, the need for acute hospitalization, mechanical ventilation, and death.
Percutaneous implantation of interatrial shunts generally requires transseptal catheterization immediately preceding shunt device insertion. The transseptal catheterization system is placed from an entrance site in the femoral vein, across the interatrial septum in the region of fossa ovalis (FO), which is the central and thinnest region of the interatrial septum. The FO in adults is typically 15-20 mm in its major axis dimension and <3 mm in thickness, but in certain circumstances may be up to 10 mm thick. LA chamber access may be achieved using a host of different techniques familiar to those skilled in the art, including but not limited to: needle puncture, stylet puncture, screw needle puncture, and radiofrequency ablation. The passageway between the two atria is dilated to facilitate passage of a shunt device having a desired orifice size. Dilation generally is accomplished by advancing a tapered sheath/dilator catheter system or inflation of an angioplasty type balloon across the FO. This is the same general location where a congenital secundum atrial septal defect (ASD) would be located.
In view of the foregoing, it would be desirable to provide devices for delivering implantable devices to the atrial septum of the heart to reduce left atrial pressure.
The present invention overcomes the drawbacks of previously-known devices by providing apparatus for delivering a device for regulating blood pressure between a patient's left atrium and right atrium. The delivery apparatus includes a sheath having a distal region sized and shaped for percutaneous advancement to the atrial septum, a proximal region, and a sheath lumen extending therethrough, the sheath lumen sized and shaped to receive the shunt in a contracted delivery state. The apparatus also includes a first, outer catheter moveably disposed within the sheath lumen, wherein the first catheter has a first catheter lumen extending therethrough, and a hub moveably disposed within the sheath lumen distal to the first catheter.
The hub has a hub lumen extending therethrough and one or more engagers sized and shaped to releasably engage the shunt in the contracted delivery state within the sheath lumen. The hub may include an engagement portion and a ring portion, wherein the engagement portion of the hub has a diameter smaller than a diameter of the ring portion, and wherein the one or more engagers are disposed circumferentially around the engagement portion of the hub. For example, a first expandable end of the shunt may be positioned between the one or more engagers and the ring portion and between an outer surface of the engagement portion and an inner wall of the sheath in the contracted delivery state within the sheath lumen. The hub further may include a proximal portion, such that the first catheter has a cavity sized and shaped to receive at least a portion of the proximal portion to limit movement of the hub relative to the first catheter.
In addition, the apparatus further includes a second, inner catheter moveably disposed within the first catheter lumen and the hub lumen, and wherein the first catheter and the hub are movable which the second catheter remains in place. The second catheter may include a stop, e.g., a lock ring, disposed at a distal end of the second catheter, such that the hub has a cavity sized and shaped to receive at least a portion of the stop to limit movement of the hub relative to the second catheter. In addition, the second catheter may include a guidewire lumen extending therethrough sized and shaped to receive a guidewire.
The apparatus also includes a handle disposed at the proximal region of the sheath. The first catheter, the hub, and the second catheter are independently movable relative to the sheath responsive to actuation at the handle to facilitate transition of the shunt from the contracted delivery state to an expanded deployed state at the atrial septum. In addition, the handle includes a knob that when actuated facilitates deployment of and/or halfway retrieval of the shunt at the atrial septum by adjusting a length of the delivery apparatus relative to the sheath. For example, the knob may be actuated to gradually adjust the length of the delivery apparatus relative to the sheath to assist in halfway retrieval of the shunt.
The handle may include a first actuator, the first actuator coupled to the sheath such that actuation of the first actuator causes the sheath to move relative to the hub, the first catheter, and the second catheter. The handle also may include a second actuator, the second actuator coupled to the second catheter such that actuation of the second actuator causes the second catheter to move relative to the sheath, the hub, and the first catheter. For example, the second actuator may be coupled to the second catheter via one or more guiderails and a pusher plate. Accordingly, the first actuator may move along the one or more guiderails within a housing of the handle.
The apparatus also includes a locking mechanism for releasably coupling the hub and the first catheter. Thus, the handle further includes a third actuator operatively coupled to the locking mechanism such that actuation of the third actuator causes the locking mechanism to couple or decouple the hub and the first catheter. The handle further may include an actuation ring positioned between the second actuator and the third actuator, wherein the actuation ring has an indented distal edge sized and shaped to engage with a toothed proximal edge of the third actuator, and a grooved proximal edge sized and shaped to engage with an indented distal edge of the second actuator. For example, actuation of the third actuator may orient the actuation ring such that actuation of the second actuator is inhibited.
In accordance with another aspect of the invention, a method for delivering a shunt at an atrial septum of a patient is provided. The method includes selecting a sheath and a delivery apparatus including a first, outer catheter, a hub distal to and releasably coupled to the first catheter, the hub having one or more engagers disposed thereon, the one or more engagers sized and shaped to releasably engage with the shunt in a contracted delivery state within a lumen of the sheath, and a second, inner catheter extending through a center lumen of the first catheter and the hub. The first catheter, the hub, and the second catheter are independently moveable relative to the sheath upon actuation of a handle operatively coupled to the sheath and the delivery apparatus.
The method further includes advancing a distal end of the sheath through the atrial septum into a first atrium, and then advancing the delivery apparatus within the lumen of the sheath, and actuating the handle to move the delivery apparatus distally relative to the sheath such that a first expandable end of the shunt extends distally out the distal end of the sheath and transitions from a contracted state within the lumen of the sheath to an expanded state in the first atrium. The method then includes (1) actuating the handle to move the second catheter distally relative to the sheath, the first catheter, and the hub; (2) moving the delivery apparatus and the sheath proximally until the first expandable end of the shunt rests against the atrial septum from within the first atrium; and (3) actuating the handle to decouple the hub and the first catheter. The method further includes moving the first catheter and the sheath proximally relative to the hub to disengage a second expandable end of the shunt with the one or more engagers of the hub and expose the second expandable end of the shunt from the sheath to transition from the contracted state within the lumen of the sheath to an expanded state in a second atrium. Finally, the method includes removing the sheath and the delivery apparatus from the patient such that a neck region of the shunt is positioned within the atrial septum to permit blood to flow through an opening in the neck region of the shunt and thereby through the atrial septum.
In accordance with one aspect of the invention, the method further includes actuating the handle to adjust a length of the delivery apparatus relative to a length of the sheath prior to disengaging the second expandable end of the shunt with the one or more engagers of the hub to assist in halfway retrieval of the shunt. For example, the handle may be actuated to gradually adjust the length of the delivery apparatus relative to the length of the sheath to facilitate retrieving the shunt in a partially deployed state. In accordance with yet another aspect of the invention, the second catheter includes a guidewire lumen extending therethrough sized and shaped to receive a guidewire, such that the method also includes inserting a guidewire percutaneously through the atrial septum into the first atrium. Thus, advancing the delivery apparatus through the sheath includes advancing the delivery apparatus over the guidewire. As will be understood by a person ordinarily skilled in the art, a dilator may be advanced over the guidewire through the fossa ovalis to enlarge the opening within the atrial septum, and removed prior to advancing the sheath and the delivery apparatus within the lumen of the sheath over the guidewire.
Embodiments of the present invention are directed to devices for delivering implantable devices to the atrial septum of the heart, and thus may be useful in treating subjects suffering from heart failure or other disorders associated with elevated left atrial pressure. For example, the inventive device may be designed to deliver an hourglass or “diabolo” shaped stent, preferably formed of a shape memory metal as described in U.S. Pat. No. 9,629,715 to Nitzan, assigned to the assignee of the present invention, the entire contents of which are incorporated herein by reference. The delivery device is configured to lodge the stent securely in the atrial septum, preferably the fossa ovalis, to function as an interatrial shunt, allowing blood flow from the left atrium to the right atrium.
Referring to
Referring now to
Release ring 146 is coupled to latching legs 112, 114, and 116. For example, latching legs 112, 114, and 116 may be partially disposed within release ring 146 as illustrated in
Annular member 148 may be partially disposed in the proximal end of cover tube 124 and configured to couple cover tube 124 to catheter 104 via a suitable coupling mechanism, e.g., teeth 150, ribs. Annular member 148 includes lumen 152 sized to accept pull-cord 154 therethrough.
Pull-cord 154 is coupled to release ring 146 and actuation of pull-cord 154 moves release ring 146 from the first position shown in
Pull-cord 154 may be coupled to release ring 146 via release ring base 156. In this embodiment, release ring base 156 is directly coupled to release ring 146 and pull-cord 154 such that actuation of pull-cord 154 moves release ring base 156 to move release ring 146 from the first position the second position, and vice versa.
Spring 158 may be coupled to the proximal surface of release ring base 156 and the distal surface of annular member 148 such that release ring base 156 and annular member 148 maintain spring 158 therebetween. Spring 158 is configured to bias release ring 146 towards a particular position such as towards the first position as shown in
Referring to
Then, the device is collapsed radially to a contracted, delivery state and coupled to the delivery apparatus (step 502). For example, as illustrated in
In
Referring to
Referring back to
The fossa ovalis (particularly its central region) may be punctured with the trans-septal puncture device, and a guidewire may be inserted through the puncture by threading the guidewire through the needle into the left atrium, and then removing the needle (step 504). The puncture through the fossa ovalis then may be expanded by advancing a dilator over the guidewire through the puncture (step 505). Alternatively, a dilator may be advanced over the trans-septal puncture device, without the need for a guidewire. The dilator is used to further dilate the puncture and a sheath then is advanced over the dilator and through the fossa ovalis; the dilator and guidewire or needle then are removed. The sheath, which may be 14 Fr., is then flushed.
Distal end 102 of apparatus 100, with device 400 coupled thereto in a contracted, delivery state, then is advanced into the sheath (step 506). For example, the delivery system may be flushed, e.g., via fluid connected to fluid tube 630, and then loading cartridge 614 may be coupled to sheath 626, e.g., via port 627, as illustrated in
Then, under fluoroscopic and/or echocardiographic visualization, sheath 626 may be repositioned such that the distal tip of sheath 626 is disposed a predetermined distance, e.g., approximately 1-2 cm, distal to the fossa ovalis within the left atrium. Next, device 400 and apparatus 100 are advanced distally such that the device is partially advanced out of the sheath so the first flared end of the device protrudes out of the sheath and into the left atrium, and expands to its deployed state (step 507). For example, device 400 and apparatus 100 may be advanced distally until the handle at proximal end 106 contacts knob 622 as shown in
As another example, the angle θ″ may be substantially less than 90 degrees as shown in
An hourglass shape may aid in non-perpendicular deployment because the flared ends of the device engage the atrial septum, even when positioned at an angle relative to the central axis of the puncture through the atrial septum.
Next, under fluoroscopic and/or echocardiographic visualization, it is verified that the first flared end of the device protrudes from sheath 626 and then knob 622 of Tuohy-Borst connector 620 is used to lock the delivery system in place within the sheath 626. Sheath 626, along with the delivery system 100 are pulled proximally causing the first flared end region of device 400 to engage the left side of the atrial septum AS as shown in
Using fluoroscopic and/or echocardiographic visualization, the clinician next verifies that the device is positioned across the fossa ovalis. The clinician then reduces the pulling force of the sheath and allows the fossa ovalis to straighten. Then, while holding sheath 626 in place, knob 622 is released and the components at distal end 102 of apparatus 100 are moved from an engaged position to a disengaged position, e.g., by actuating handle 108 as shown in
The shunt device then may be fully deployed by pulling the sheath proximally causing the first flared end region to engage the left side of the atrial septum and the neck of the device to lodge in the puncture through the fossa ovalis, and allowing expansion of the second flared end of the device into the right atrium as shown in
Referring to
Like handle 108, handle 708 may be manipulated, for example, by moving finger grips 710 proximally from a locked position shown to an unlocked position. In addition, handle 708 may be manipulated by moving finger grips 710 distally from the locked position to the unlocked position so as to transition components in distal end 702 from the disengaged position to the engaged position to load devices of the present invention. Handle 708 also may include securement mechanism 709 coupled to handle safety lock 711 such that finger grips 710 cannot be moved until handle safety lock 711 is released. Upon activation, handle 708 is retained in position, enabling a single user to perform the procedure.
In one embodiment, hook portions 718, 720, and 722 move generally radially away from center axis 723. The angle between the lower surface of the hook portion and the longitudinal axis of the latching leg is preferably less than 90 degrees and greater than 75 degrees, e.g., 87 degrees, as shown in
Catheter 704 may include cover tube 724 which may have a larger diameter than the remaining shaft of catheter 704. Cover tube 724 comprises a biocompatible material such as a biocompatible metal or polymer, and may be the same or different material than the remaining shaft of catheter 704. Components at distal end 702, such as latching legs 712, 714, and 716, may be at least partially disposed within cover tube 724. Referring back to
Referring now to
Release ring 746 is coupled to latching legs 712, 714, and 716. For example, latching legs 712, 714, and 716 may be partially disposed within release ring 746 as illustrated in
Annular member 748 may be partially disposed in the proximal end of cover tube 724 and configured to couple cover tube 724 to catheter 704 via a suitable coupling mechanism, e.g., teeth 750, ribs. Annular member 748 includes lumen 752 sized to accept control tube 707 therethrough.
Control tube 707 is coupled to release ring 746 and actuation of control tube 707 moves release ring 746 from the first position shown in
Control tube 707 may be coupled to release ring 746 via release ring base 756. In this embodiment, release ring base 756 is directly coupled to release ring 746 and control tube 707 such that actuation of control tube 707 moves release ring base 756 to move release ring 746 from the first position the second position, and vice versa.
Spring 758 may be coupled to the proximal surface of release ring base 756 and the distal surface of annular member 748 such that release ring base 756 and annular member 748 maintain spring 758 therebetween. Spring 758 is configured to bias release ring 746 towards a particular position such as towards the first position as shown in
At step 1106, distal end 702 of apparatus 700, with device 400 coupled thereto, is advanced through the sheath over the guidewire until proximal end 706 of apparatus 700 is a predetermined distance from the proximal end of the sheath such that distal end 702 of apparatus 700 is a predetermined distance from the distal end of the sheath. The guidewire is received from the Luer connector 705 via lumen 755 of control tube 707. Steps 1107-1110 are similar to steps 507-510 described in
In accordance with another aspect of the present invention, knob system 703 may be used for length adjustment of apparatus 700 relative to the sheath during deployment of device 400 at the atrial septum, e.g., to assist in halfway retrieval of device 400. For example, referring now to
Referring now to
Referring to
Referring to
Exemplary method 1500 of delivering device 400 to reduce left atrial pressure in a subject, for example, a human having a heart pathology, using apparatus 1400 illustrated in
In addition, handle 1408 includes knob 1401. The inner components of knob 1401 includes a threaded portion that corresponds with a threaded portion coupled to sheath 1410. Accordingly, as knob 1401 is rotated about the longitudinal axis of handle 1408, rotational movement of knob 1401 is converted to translational movement of the threaded portion coupled to sheath 1410 along the longitudinal axis of handle 1408, thereby causing movement of sheath 1410 relative to catheter 1404. This permits gradual adjustment of the length of sheath 1410 relative to catheter 1404, and accordingly halfway-retrieval of device 400 when device is halfway deployed as will be described in further detail below. Knob 1401 may not be rotated until third actuator 1424 is moved from a locked position to an unlocked position.
As illustrated in
When third actuator 1424 is moved to the second position, such that third actuator component 1413 is rotated, e.g., counter-clockwise, about the longitudinal axis of handle 1408, the space between the edge of the tooth of third actuator component 1413 and the edge of the indent of actuator ring 1415 increases such that actuator ring 1415 is free to rotate in the same direction, e.g., counter-clockwise until the edge of the indent of actuator ring 1415 engages with the edge of the tooth of third actuator component 1413. In addition, third actuator component 1413 is operatively coupled to a locking mechanism between inner catheter 1411 and a hub disposed within the distal region of sheath 1410 as described in further detail below.
Actuator ring 1415 also may include a grooved pattern along its proximal end for engaging with a corresponding indent along the distal end of second actuator component 1417 coupled to second actuator 1423. Accordingly, the edge of the tooth of third actuator component 1413 may further engage with the indent of actuator ring 1415, to thereby rotate actuator ring 1415 until the groove of actuator ring 1415 engages with the indent of second actuator component 1417. Second actuator 1423 may be moveable between a first and second position. For example,
First actuator component 1419 is moveable along the longitudinal axis of handle 1408, parallel to inner catheter 1411, between a first and second position. For example,
First actuator component 1419 includes a lumen sized and shaped to receive centering element 1429, wherein centering element 1429 is fixed relative to handle 1408. First actuator 1422 is further coupled to proximal portion 1427 sized and shaped to move within a lumen of centering element 1429. Proximal portion 1427 includes a lumen sized and shaped to receive inner catheter 1411, such that proximal portion 1427 is moveable between the first and second positions along inner catheter 1411. First actuator 1422 may be moveably coupled to inner catheter 1411 via proximal portion 1427, and may include port 1439 for coupling to a fluid source to introduce fluid into the guidewire lumen of inner catheter 1411 for flushing. In addition, first actuator component 1419 is coupled to sheath 1410 for extending and retracting the distal end of sheath 1410 as described in further detail below.
In addition, hub 1412 includes one or more engagers, e.g., protrusions 1414, 1416 and 1418, extending radially outward from a central axis of catheter 1404, such that the one or more engagers are disposed circumferentially about the outer surface of hub 1412, e.g., at engagement portion 1428, and are configured to fit securely between struts and rings of the interatrial devices for delivery. Thus, each of the one or more engagers may be sized to engage device 400 in openings between rings 402 and struts 404 when device 400 is in a contracted, delivery state. For example, the distance from the central axis of hub 1412 to the outermost surface of each of the one or more engagers is equal to or slightly less than the inner radius of sheath 1410 so that hub 1412 may be moveable within sheath 1410. The distance from the central axis of hub 1412 to the outermost surface of each of the one or more engagers may be equal to the distance from the central axis of hub 1412 to the outer surface of ring portion 1426. Accordingly, device 400 may be constrained between the one or more engagers and ring portion 1426, and between engagement portion 1428 and sheath 1410 in order to prevent dislodgement or early deployment of device 400 within sheath 1410. As shown in
In addition, inner catheter 1411 is disposed within a central lumen extending through hub 1412 and catheter 1404. Inner catheter 1411 may include a stop, e.g., lock ring 1438, fixed at a distal end of inner catheter 1411, wherein lock ring 1438 is sized and shaped to be disposed within cavity 1430 of hub 1412. Cavity 1430 may extend through at least a portion of engagement portion 1428 of hub 1412, or completely through engagement portion 1428 of hub 1412 and at least a portion of ring portion 1426 of hub 1412. Lock ring 1438 ensures that hub 1412 does not extend beyond a predetermined distance distally along inner catheter 1411, and that inner catheter 1411 does not retract beyond the predetermined distance proximally relative to hub 1412. Inner catheter 1411 also may include guidewire lumen 1425 sized and shaped to receive a guidewire therethrough. For example, delivery apparatus 1400 may be advanced over a guidewire such that the distal end of sheath 1410 having distal end 1402 coupled to device 400 disposed therein, is positioned across the fossa ovalis.
Referring now to
Referring now to
Referring back to
If for any reason device 400 is not in the proper position for deployment within the atrial septum, sheath 1410 may be advanced over device 400 while catheter 1404 is stationary, thereby collapsing first flared end region 401 within sheath 1410. Specifically, knob 1401 of handle 1408 may be rotated to cause sheath 1410 to move translationally relative to catheter 1404 and device 400, to thereby collapse device 400 within sheath 1410. For example, sheath 1410 may be moved over collapsed device 400 until device 400 is completely collapsed within sheath 1410. Distal end 1402, with device 400 disposed therein, may then be retrieved. Alternatively, distal end 1402 may be repositioned relative to the fossa ovalis of the atrial septum prior to partially advancing first flared end region 401 out of sheath 1410 within the left atrium.
When third actuator 1424 is in the second position and hub 1412 and catheter 1404 are decoupled, the delivery apparatus may be pulled proximally by the physician such that the atrial septum maintains device 400 in position against the left side of the atrial septum until second flared end region 403 of device 400 is no longer constrained between hub 1412 and sheath 1410 as shown in
Referring back to
Any remaining components of the delivery system then may be removed, e.g., sheath, distal end of delivery apparatus, the catheter, and the guidewire (step 1510). Once positioned in the fossa ovalis as shown in
It should be noted that the inventive devices also may be used with patients having disorders other than heart failure. For example, in one embodiment the device may be implanted in a subject suffering from myocardial infarction, for example in the period immediately following myocardial infarction (e.g., within a few days of the event, or within two weeks of the event, or even within six months of the event). During such a period, the heart remodels to compensate for reduced myocardial function. For some subjects suffering from severe myocardial infarction, such remodeling may cause the function of the left ventricle to significantly deteriorate, which may lead to development of heart failure. Implanting an inventive device during the period immediately following myocardial infarction may inhibit such deterioration in the left ventricle by reducing LAP and LVEDP during the remodeling period. The device optionally then may be removed as described in further detail below.
Exemplary method 1700 of retrieving device 400 from a subject, for example, from a puncture through the fossa ovalis, will now be described with reference to
At step 1702, a guidewire is inserted through the neck of the implanted shunt device through the fossa ovalis of the atrial septum into the left atrium. The guidewire may be inserted using techniques readily known in the art. At step 1703, the sheath is inserted over the guidewire and positioned in proximity to the flared end region of the shunt device disposed in right atrium. The guidewire may then be removed. At step 1704, the retrieval catheter and the restraint member are delivered through the sheath in proximity to the flared end region of the shunt device disposed in right atrium.
At step 1705, retrieval catheter 1804 along with restraint member 1808 are advanced distally and exposed beyond the distal end of sheath 1802 within the right atrium such that hook portions 1806 are within at least a portion of second flared end region 403 of device 400, as illustrated in
At step 1708, while hook portions 1806 are maintained in placed and engaged with second flared end region 403 of device 400, restraint member 1808 is advanced distally toward hook portions 1806 via control tube 1810, thereby causing hook portions 1806, and accordingly second flared end region 403, to transition to a compressed configuration, as illustrated in
In accordance with another aspect of the present invention, exemplary method 1900 of retrieving device 400 from a subject, for example, from a puncture through the fossa ovalis, will now be described with reference to
At step 1902, a guidewire is inserted through the neck of the implanted shunt device through the fossa ovalis of the atrial septum into the left atrium. The guidewire may be inserted using techniques readily known in the art. At step 1903, the sheath is inserted over the guidewire and positioned in proximity to the flared end region of the shunt device disposed in right atrium. At step 1904, the grappling hook and the inflatable balloon catheter are delivered through the sheath over the guidewire in proximity to the flared end region of the shunt device disposed in right atrium.
At step 1905, inflatable balloon catheter 2008 is advanced distally, e.g., over the guidewire (not shown), and exposed beyond the distal end of sheath 2002 within the right atrium in a deflated condition such that inflatable balloon catheter 2008 is positioned within at least a portion of second flared end region 403 of device 400, as illustrated in
At step 1907, grappling hook 2004 is advanced distally and exposed beyond the distal end of sheath 2002 within the right atrium. As illustrated in
At step 1909, while hook portions 2006 are maintained in placed and engaged with second flared end region 403 of device 400, inflatable balloon catheter 2008 is deflated and advanced distally into the left atrium. Alternatively, inflatable balloon catheter 2008 may be deflated and removed from the patient's body or deflated and retracted into a balloon channel within sheath 2002. Deflation of inflatable balloon catheter 2008 causes hook portions 2006 of grappling hook 2004, and accordingly second flared end region 403, to transition to a compressed configuration, as illustrated in
Next, at step 1910, sheath 2002 is advanced distally over grappling hook 2004, device 400, and inflatable balloon catheter 2008, through the atrial septum AS and into the left atrium, thereby causing first flared end region 401 of device 400 to transition to a compressed configuration within sheath 2002, as illustrated in
Referring to
Referring now to
Exemplary method 2300 of using loading tool 2200 to load device 400 into apparatus 2100 will now be described with reference to
In accordance with the principles of the present invention, the latching legs and hook portions of engagement apparatus 2120 may be actuated to be in a disengaged position, e.g., contracted inward, before proximal loader 2202 is completely advanced within distal loader 2204 so that the engagement hooks of engagement apparatus 2120 may be appropriately aligned with the struts of second flared end region 403 of device 400, and so that second flared end region 403 can smoothly enter lumen 2208 of proximal loader 2202. Once aligned, the latching legs and hook portions of engagement apparatus 2120 may be actuated to be in a engaged position to engage with second flared end region 403 of device 400 within lumen 2208 of proximal loader 2202 (step 2305).
Exemplary method 2700 of delivering device 400 to reduce left atrial pressure in a subject, for example, a human having a heart pathology, using apparatus 2100 illustrated in
At step 2701, an interatrial shunt, e.g., device 400, and apparatus 2100 of
Pigtail-shaped portion 2112 of distal tip 2110 of delivery apparatus 2100 with device 400 collapsed therein and coupled to engagement apparatus 2120 of apparatus 2100 is then advanced over guidewire 2801 through the puncture in the fossa ovalis and into left atrium LA (step 2705) as illustrated in
Then, under fluoroscopic and/or echocardiographic visualization, apparatus 2100 may be repositioned such that radiopaque marker 2801 is aligned with the fossa ovalis (step 2707) as illustrated in
If for any reason device 400 is not in the proper position for deployment within the atrial septum, catheter 2104 may be advanced over device 400 while distal tip 2110 is stationary, thereby collapsing the first flared end region within catheter 2104 (step 2708) as illustrated in
After step 2707 described above, when device 400 is properly positioned relative to the atrial septum, engagement apparatus 2120 may be disengaged from device 400, e.g., hook portions 2118 may be moved from an engaged positioned radially inward to a disengaged position. Then, catheter 2104 may be retracted proximally relative to distal tip 2110, causing the second flared end region of device 400 to be exposed within right atrium RA beyond the distal end of catheter 2104 such that the second flared end region transitions from the collapsed delivery state to an expanded state within right atrium RA (step 2710) as illustrated in
As illustrated in
Referring now to
In addition, guidewire loading tool 2900 has central lumen 2905 extending through proximal portion 2903 and distal portion 2901, sized and shaped to receive loading cartridge 614 therein, e.g., when device 400 is collapsed in a delivery state within loading cartridge 614 as described above with reference to
Referring now to
Next, as illustrated in
While various illustrative embodiments of the invention are described above, it will be apparent to one skilled in the art that various changes and modifications may be made herein without departing from the invention. It will further be appreciated that the devices described herein may be implanted in other positions in the heart. For example, device 400 may be implanted in an orientation so as to shunt blood from the right atrium to the left atrium, thus decreasing right atrial pressure; such a feature may be useful for treating a high right atrial pressure that occurs in pulmonary hypertension. Similarly, device 400 may be implanted across the ventricular septum, in an orientation suitable to shunt blood from the left ventricle to the right ventricle, or in an orientation suitable to shunt blood from the right ventricle to the left ventricle. The appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3852334 | Dusza et al. | Dec 1974 | A |
| 3874388 | King et al. | Apr 1975 | A |
| 3952334 | Bokros et al. | Apr 1976 | A |
| 4484955 | Hochstein | Nov 1984 | A |
| 4601309 | Chang | Jul 1986 | A |
| 4617932 | Kornberg | Oct 1986 | A |
| 4662355 | Pieronne et al. | May 1987 | A |
| 4665906 | Jervis | May 1987 | A |
| 4705507 | Boyles | Nov 1987 | A |
| 4836204 | Landymore et al. | Jun 1989 | A |
| 4979955 | Smith | Dec 1990 | A |
| 4988339 | Vadher | Jan 1991 | A |
| 4995857 | Arnold | Feb 1991 | A |
| 5035702 | Taheri | Jul 1991 | A |
| 5035706 | Giantureo et al. | Jul 1991 | A |
| 5037427 | Harada et al. | Aug 1991 | A |
| 5089005 | Harada | Feb 1992 | A |
| 5186431 | Tamari | Feb 1993 | A |
| 5197978 | Hess | Mar 1993 | A |
| 5234447 | Kaster et al. | Aug 1993 | A |
| 5267940 | Moulder | Dec 1993 | A |
| 5290227 | Pasque | Mar 1994 | A |
| 5312341 | Turi | May 1994 | A |
| 5326374 | Ilbawi et al. | Jul 1994 | A |
| 5332402 | Teitelbaum | Jul 1994 | A |
| 5334217 | Das | Aug 1994 | A |
| 5378239 | Termin et al. | Jan 1995 | A |
| 5409019 | Wilk | Apr 1995 | A |
| 5429144 | Wilk | Jul 1995 | A |
| 5500015 | Deac | Mar 1996 | A |
| 5531759 | Kensey et al. | Jul 1996 | A |
| 5545210 | Hess et al. | Aug 1996 | A |
| 5556386 | Todd | Sep 1996 | A |
| 5578008 | Hara | Nov 1996 | A |
| 5584803 | Stevens et al. | Dec 1996 | A |
| 5597377 | Aldea | Jan 1997 | A |
| 5645559 | Hachtman et al. | Jul 1997 | A |
| 5655548 | Nelson et al. | Aug 1997 | A |
| 5662711 | Douglas | Sep 1997 | A |
| 5702412 | Popov et al. | Dec 1997 | A |
| 5725552 | Kotula et al. | Mar 1998 | A |
| 5741324 | Glastra | Apr 1998 | A |
| 5749880 | Banas et al. | May 1998 | A |
| 5779716 | Cano et al. | Jul 1998 | A |
| 5795307 | Krueger | Aug 1998 | A |
| 5810836 | Hussein et al. | Sep 1998 | A |
| 5824062 | Patke et al. | Oct 1998 | A |
| 5824071 | Nelson et al. | Oct 1998 | A |
| 5846261 | Kotula et al. | Dec 1998 | A |
| 5910144 | Hayashi | Jun 1999 | A |
| 5916193 | Stevens et al. | Jun 1999 | A |
| 5941850 | Shah et al. | Aug 1999 | A |
| 5957949 | Leonhardt et al. | Sep 1999 | A |
| 5990379 | Gregory | Nov 1999 | A |
| 6027518 | Gaber | Feb 2000 | A |
| 6039755 | Edwin et al. | Mar 2000 | A |
| 6039759 | Carpentier et al. | Mar 2000 | A |
| 6086610 | Duerig et al. | Jul 2000 | A |
| 6111520 | Allen et al. | Aug 2000 | A |
| 6117159 | Huebsch et al. | Sep 2000 | A |
| 6120534 | Ruiz | Sep 2000 | A |
| 6124523 | Banas et al. | Sep 2000 | A |
| 6126686 | Badylak et al. | Oct 2000 | A |
| 6165188 | Saadat et al. | Dec 2000 | A |
| 6210318 | Lederman | Apr 2001 | B1 |
| 6214039 | Banas et al. | Apr 2001 | B1 |
| 6217541 | Yu | Apr 2001 | B1 |
| 6221096 | Aiba et al. | Apr 2001 | B1 |
| 6231587 | Makower | May 2001 | B1 |
| 6242762 | Brown et al. | Jun 2001 | B1 |
| 6245099 | Edwin et al. | Jun 2001 | B1 |
| 6254564 | Wilk et al. | Jul 2001 | B1 |
| 6260552 | Mortier et al. | Jul 2001 | B1 |
| 6264684 | Banas et al. | Jul 2001 | B1 |
| 6270515 | Linden et al. | Aug 2001 | B1 |
| 6270526 | Cox | Aug 2001 | B1 |
| 6277078 | Porat et al. | Aug 2001 | B1 |
| 6278379 | Allen et al. | Aug 2001 | B1 |
| 6302892 | Wilk | Oct 2001 | B1 |
| 6306141 | Jervis | Oct 2001 | B1 |
| 6328699 | Eigler et al. | Dec 2001 | B1 |
| 6344022 | Jarvik | Feb 2002 | B1 |
| 6358277 | Duran | Mar 2002 | B1 |
| 6391036 | Berg et al. | May 2002 | B1 |
| 6398803 | Layne et al. | Jun 2002 | B1 |
| 6406422 | Landesberg | Jun 2002 | B1 |
| 6447539 | Nelson et al. | Sep 2002 | B1 |
| 6451051 | Drasler et al. | Sep 2002 | B2 |
| 6458153 | Bailey et al. | Oct 2002 | B1 |
| 6468303 | Amplatz et al. | Oct 2002 | B1 |
| 6475136 | Forsell | Nov 2002 | B1 |
| 6478776 | Rosenman et al. | Nov 2002 | B1 |
| 6485507 | Walak et al. | Nov 2002 | B1 |
| 6488702 | Besselink | Dec 2002 | B1 |
| 6491705 | Gifford et al. | Dec 2002 | B2 |
| 6527698 | Kung et al. | Mar 2003 | B1 |
| 6544208 | Ethier et al. | Apr 2003 | B2 |
| 6547814 | Edwin et al. | Apr 2003 | B2 |
| 6562066 | Martin | May 2003 | B1 |
| 6572652 | Shaknovich | Jun 2003 | B2 |
| 6579314 | Lombardi et al. | Jun 2003 | B1 |
| 6589198 | Soltanpour et al. | Jul 2003 | B1 |
| 6616675 | Evard et al. | Sep 2003 | B1 |
| 6632169 | Korakianitis et al. | Oct 2003 | B2 |
| 6638303 | Campbell | Oct 2003 | B1 |
| 6641610 | Wolf et al. | Nov 2003 | B2 |
| 6652578 | Bailey et al. | Nov 2003 | B2 |
| 6685664 | Levin et al. | Feb 2004 | B2 |
| 6712836 | Berg et al. | Mar 2004 | B1 |
| 6740115 | Lombardi et al. | May 2004 | B2 |
| 6758858 | McCrea et al. | Jul 2004 | B2 |
| 6764507 | Shanley et al. | Jul 2004 | B2 |
| 6770087 | Layne et al. | Aug 2004 | B2 |
| 6797217 | McCrea et al. | Sep 2004 | B2 |
| 6890350 | Walak | May 2005 | B1 |
| 6923829 | Boyle et al. | Aug 2005 | B2 |
| 6970742 | Mann et al. | Nov 2005 | B2 |
| 7001409 | Amplatz | Feb 2006 | B2 |
| 7004966 | Edwin et al. | Feb 2006 | B2 |
| 7025777 | Moore | Apr 2006 | B2 |
| 7060150 | Banas et al. | Jun 2006 | B2 |
| 7083640 | Lombardi et al. | Aug 2006 | B2 |
| 7115095 | Eigler et al. | Oct 2006 | B2 |
| 7118600 | Dua et al. | Oct 2006 | B2 |
| 7137953 | Eigler et al. | Nov 2006 | B2 |
| 7147604 | Allen et al. | Dec 2006 | B1 |
| 7149587 | Wardle et al. | Dec 2006 | B2 |
| 7169160 | Middleman et al. | Jan 2007 | B1 |
| 7169172 | Levine et al. | Jan 2007 | B2 |
| 7195594 | Eigler et al. | Mar 2007 | B2 |
| 7208010 | Shanley et al. | Apr 2007 | B2 |
| 7226558 | Nieman et al. | Jun 2007 | B2 |
| 7245117 | Joy et al. | Jul 2007 | B1 |
| 7294115 | Wilk | Nov 2007 | B1 |
| 7306756 | Edwin et al. | Dec 2007 | B2 |
| 7402899 | Whiting et al. | Jul 2008 | B1 |
| 7439723 | Allen et al. | Oct 2008 | B2 |
| 7468071 | Edwin et al. | Dec 2008 | B2 |
| 7483743 | Mann et al. | Jan 2009 | B2 |
| 7498799 | Allen et al. | Mar 2009 | B2 |
| 7509169 | Eigler et al. | Mar 2009 | B2 |
| 7550978 | Joy et al. | Jun 2009 | B2 |
| 7578899 | Edwin et al. | Aug 2009 | B2 |
| 7590449 | Mann et al. | Sep 2009 | B2 |
| 7615010 | Najafi et al. | Nov 2009 | B1 |
| 7621879 | Eigler et al. | Nov 2009 | B2 |
| 7679355 | Allen et al. | Mar 2010 | B2 |
| 7717854 | Mann et al. | May 2010 | B2 |
| 7794473 | Tessmer et al. | Sep 2010 | B2 |
| 7839153 | Joy et al. | Nov 2010 | B2 |
| 7842083 | Shanley et al. | Nov 2010 | B2 |
| 7854172 | O'Brien et al. | Dec 2010 | B2 |
| 7862513 | Eigler et al. | Jan 2011 | B2 |
| 7914639 | Layne et al. | Mar 2011 | B2 |
| 7939000 | Edwin et al. | May 2011 | B2 |
| 7988724 | Salahieh et al. | Aug 2011 | B2 |
| 7993383 | Hartley et al. | Aug 2011 | B2 |
| 8012194 | Edwin et al. | Sep 2011 | B2 |
| 8016877 | Seguin et al. | Sep 2011 | B2 |
| 8021420 | Dolan | Sep 2011 | B2 |
| 8025625 | Allen | Sep 2011 | B2 |
| 8025668 | McCartney | Sep 2011 | B2 |
| 8043360 | McNamara et al. | Oct 2011 | B2 |
| 8070708 | Rottenberg et al. | Dec 2011 | B2 |
| 8091556 | Keren et al. | Jan 2012 | B2 |
| 8096959 | Stewart et al. | Jan 2012 | B2 |
| 8137605 | McCrea et al. | Mar 2012 | B2 |
| 8142363 | Eigler et al. | Mar 2012 | B1 |
| 8147545 | Avior | Apr 2012 | B2 |
| 8157852 | Bloom et al. | Apr 2012 | B2 |
| 8157860 | McNamara et al. | Apr 2012 | B2 |
| 8157940 | Edwin et al. | Apr 2012 | B2 |
| 8158041 | Colone | Apr 2012 | B2 |
| 8187321 | Shanley et al. | May 2012 | B2 |
| 8202313 | Shanley et al. | Jun 2012 | B2 |
| 8206435 | Shanley et al. | Jun 2012 | B2 |
| 8235916 | Whiting et al. | Aug 2012 | B2 |
| 8235933 | Keren et al. | Aug 2012 | B2 |
| 8246677 | Ryan | Aug 2012 | B2 |
| 8287589 | Otto et al. | Oct 2012 | B2 |
| 8298150 | Mann et al. | Oct 2012 | B2 |
| 8298244 | Garcia et al. | Oct 2012 | B2 |
| 8303511 | Eigler et al. | Nov 2012 | B2 |
| 8313524 | Edwin et al. | Nov 2012 | B2 |
| 8328751 | Keren et al. | Dec 2012 | B2 |
| 8337650 | Edwin et al. | Dec 2012 | B2 |
| 8348996 | Tuval et al. | Jan 2013 | B2 |
| 8357193 | Phan et al. | Jan 2013 | B2 |
| 8398708 | Meiri et al. | Mar 2013 | B2 |
| 8460366 | Rowe | Jun 2013 | B2 |
| 8468667 | Straubinger et al. | Jun 2013 | B2 |
| 8480594 | Eigler et al. | Jul 2013 | B2 |
| 8579966 | Seguin et al. | Nov 2013 | B2 |
| 8597225 | Kapadia | Dec 2013 | B2 |
| 8617337 | Layne et al. | Dec 2013 | B2 |
| 8617441 | Edwin et al. | Dec 2013 | B2 |
| 8652284 | Bogert et al. | Feb 2014 | B2 |
| 8665086 | Miller et al. | Mar 2014 | B2 |
| 8696611 | Nitzan et al. | Apr 2014 | B2 |
| 8790241 | Edwin et al. | Jul 2014 | B2 |
| 8882697 | Celermajer et al. | Nov 2014 | B2 |
| 8882798 | Schwab et al. | Nov 2014 | B2 |
| 8911489 | Ben-Muvhar | Dec 2014 | B2 |
| 9005155 | Sugimoto | Apr 2015 | B2 |
| 9034034 | Nitzan et al. | May 2015 | B2 |
| 9055917 | Mann et al. | Jun 2015 | B2 |
| 9060696 | Eigler et al. | Jun 2015 | B2 |
| 9067050 | Gallagher et al. | Jun 2015 | B2 |
| 9205236 | McNamara et al. | Dec 2015 | B2 |
| 9220429 | Nabutovsky et al. | Dec 2015 | B2 |
| 9358371 | McNamara et al. | Jun 2016 | B2 |
| 9393115 | Tabor et al. | Jul 2016 | B2 |
| 9456812 | Finch et al. | Oct 2016 | B2 |
| 9622895 | Cohen et al. | Apr 2017 | B2 |
| 9629715 | Nitzan et al. | Apr 2017 | B2 |
| 9681948 | Levi et al. | Jun 2017 | B2 |
| 9707382 | Nitzan et al. | Jul 2017 | B2 |
| 9713696 | Yacoby et al. | Jul 2017 | B2 |
| 9757107 | McNamara et al. | Sep 2017 | B2 |
| 9789294 | Taft et al. | Oct 2017 | B2 |
| 9918677 | Eigler et al. | Mar 2018 | B2 |
| 9943670 | Keren et al. | Apr 2018 | B2 |
| 9980815 | Nitzan et al. | May 2018 | B2 |
| 10045766 | McNamara et al. | Aug 2018 | B2 |
| 10047421 | Khan et al. | Aug 2018 | B2 |
| 10076403 | Eigler et al. | Sep 2018 | B1 |
| 10105103 | Goldshtein et al. | Oct 2018 | B2 |
| 10111741 | Michalak | Oct 2018 | B2 |
| 10207087 | Keren et al. | Feb 2019 | B2 |
| 10207807 | Moran et al. | Feb 2019 | B2 |
| 10251740 | Eigler et al. | Apr 2019 | B2 |
| 10251750 | Alexander et al. | Apr 2019 | B2 |
| 10265169 | Desrosiers | Apr 2019 | B2 |
| 10299687 | Nabutovsky et al. | May 2019 | B2 |
| 10357320 | Beira | Jul 2019 | B2 |
| 10357357 | Levi et al. | Jul 2019 | B2 |
| 10368981 | Nitzan et al. | Aug 2019 | B2 |
| 10463490 | Rottenberg et al. | Nov 2019 | B2 |
| 10478594 | Yacoby et al. | Nov 2019 | B2 |
| 10548725 | Alkhatib et al. | Feb 2020 | B2 |
| 10561423 | Sharma | Feb 2020 | B2 |
| 10583002 | Lane | Mar 2020 | B2 |
| 10639459 | Nitzan et al. | May 2020 | B2 |
| 10828151 | Nitzan et al. | Nov 2020 | B2 |
| 10835394 | Nae et al. | Nov 2020 | B2 |
| 10898698 | Eigler et al. | Jan 2021 | B1 |
| 10912645 | Rottenberg et al. | Feb 2021 | B2 |
| 10925706 | Eigler et al. | Feb 2021 | B2 |
| 10940296 | Keren | Mar 2021 | B2 |
| 11234702 | Eigler et al. | Feb 2022 | B1 |
| 11253353 | Levi et al. | Feb 2022 | B2 |
| 11291807 | Eigler et al. | Apr 2022 | B2 |
| 11304831 | Nae et al. | Apr 2022 | B2 |
| 20010021872 | Bailey et al. | Sep 2001 | A1 |
| 20020120277 | Hauschild et al. | Aug 2002 | A1 |
| 20020165479 | Wilk | Nov 2002 | A1 |
| 20020165606 | Wolf et al. | Nov 2002 | A1 |
| 20020169371 | Gilderdale | Nov 2002 | A1 |
| 20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
| 20020173742 | Keren et al. | Nov 2002 | A1 |
| 20020183628 | Reich et al. | Dec 2002 | A1 |
| 20030028213 | Thill et al. | Feb 2003 | A1 |
| 20030045902 | Weadock | Mar 2003 | A1 |
| 20030100920 | Akin et al. | May 2003 | A1 |
| 20030125798 | Martin | Jul 2003 | A1 |
| 20030136417 | Fonseca et al. | Jul 2003 | A1 |
| 20030139819 | Beer et al. | Jul 2003 | A1 |
| 20030176914 | Rabkin et al. | Sep 2003 | A1 |
| 20030209835 | Chun et al. | Nov 2003 | A1 |
| 20030216679 | Wolf et al. | Nov 2003 | A1 |
| 20030216803 | Ledergerber | Nov 2003 | A1 |
| 20040010219 | McCusker et al. | Jan 2004 | A1 |
| 20040016514 | Nien | Jan 2004 | A1 |
| 20040073242 | Chanduszko | Apr 2004 | A1 |
| 20040077988 | Tweden et al. | Apr 2004 | A1 |
| 20040088045 | Cox | May 2004 | A1 |
| 20040093075 | Kuehne | May 2004 | A1 |
| 20040102797 | Golden et al. | May 2004 | A1 |
| 20040116999 | Ledergerber | Jun 2004 | A1 |
| 20040138743 | Myers et al. | Jul 2004 | A1 |
| 20040147869 | Wolf et al. | Jul 2004 | A1 |
| 20040147871 | Burnett | Jul 2004 | A1 |
| 20040147886 | Bonni | Jul 2004 | A1 |
| 20040147969 | Mann et al. | Jul 2004 | A1 |
| 20040162514 | Alferness et al. | Aug 2004 | A1 |
| 20040193261 | Berreklouw | Sep 2004 | A1 |
| 20040210190 | Kohler et al. | Oct 2004 | A1 |
| 20040210307 | Khairkhahan | Oct 2004 | A1 |
| 20040225352 | Osborne et al. | Nov 2004 | A1 |
| 20050003327 | Elian et al. | Jan 2005 | A1 |
| 20050033327 | Gainor et al. | Feb 2005 | A1 |
| 20050033351 | Newton | Feb 2005 | A1 |
| 20050065589 | Schneider et al. | Mar 2005 | A1 |
| 20050125032 | Whisenant et al. | Jun 2005 | A1 |
| 20050137682 | Justino | Jun 2005 | A1 |
| 20050148925 | Rottenberg et al. | Jul 2005 | A1 |
| 20050165344 | Dobak, III | Jul 2005 | A1 |
| 20050182486 | Gabbay | Aug 2005 | A1 |
| 20050267524 | Chanduszko | Dec 2005 | A1 |
| 20050283231 | Haug et al. | Dec 2005 | A1 |
| 20050288596 | Eigler et al. | Dec 2005 | A1 |
| 20050288706 | Widomski et al. | Dec 2005 | A1 |
| 20050288786 | Chanduszko | Dec 2005 | A1 |
| 20060009800 | Christianson et al. | Jan 2006 | A1 |
| 20060025857 | Bergheim et al. | Feb 2006 | A1 |
| 20060111660 | Wolf et al. | May 2006 | A1 |
| 20060116710 | Corcoran et al. | Jun 2006 | A1 |
| 20060122522 | Chavan et al. | Jun 2006 | A1 |
| 20060122647 | Callaghan et al. | Jun 2006 | A1 |
| 20060167541 | Lattouf | Jul 2006 | A1 |
| 20060184231 | Rucker | Aug 2006 | A1 |
| 20060212110 | Osborne et al. | Sep 2006 | A1 |
| 20060241745 | Solem | Oct 2006 | A1 |
| 20060256611 | Bednorz et al. | Nov 2006 | A1 |
| 20060282157 | Hill et al. | Dec 2006 | A1 |
| 20070010852 | Blaeser et al. | Jan 2007 | A1 |
| 20070021739 | Weber | Jan 2007 | A1 |
| 20070043435 | Seguin et al. | Feb 2007 | A1 |
| 20070129756 | Abbott et al. | Jun 2007 | A1 |
| 20070191863 | De Juan, Jr. et al. | Aug 2007 | A1 |
| 20070213813 | Von Segesser et al. | Sep 2007 | A1 |
| 20070276413 | Nobles | Nov 2007 | A1 |
| 20070276414 | Nobles | Nov 2007 | A1 |
| 20070282157 | Rottenberg et al. | Dec 2007 | A1 |
| 20070299384 | Faul et al. | Dec 2007 | A1 |
| 20080034836 | Eigler et al. | Feb 2008 | A1 |
| 20080086205 | Gordy et al. | Apr 2008 | A1 |
| 20080125861 | Webler et al. | May 2008 | A1 |
| 20080177300 | Mas et al. | Jul 2008 | A1 |
| 20080262602 | Wilk et al. | Oct 2008 | A1 |
| 20080319525 | Tieu et al. | Dec 2008 | A1 |
| 20090030499 | Bebb et al. | Jan 2009 | A1 |
| 20090054976 | Tuval et al. | Feb 2009 | A1 |
| 20090125104 | Hoffman | May 2009 | A1 |
| 20090149947 | Frohwitter | Jun 2009 | A1 |
| 20090198315 | Boudjemline | Aug 2009 | A1 |
| 20090276040 | Rowe et al. | Nov 2009 | A1 |
| 20090319037 | Rowe et al. | Dec 2009 | A1 |
| 20100004740 | Seguin et al. | Jan 2010 | A1 |
| 20100022940 | Thompson | Jan 2010 | A1 |
| 20100057192 | Celermajer | Mar 2010 | A1 |
| 20100069836 | Satake | Mar 2010 | A1 |
| 20100070022 | Kuehling | Mar 2010 | A1 |
| 20100081867 | Fishler et al. | Apr 2010 | A1 |
| 20100100167 | Bortlein et al. | Apr 2010 | A1 |
| 20100121434 | Paul et al. | May 2010 | A1 |
| 20100179590 | Fortson et al. | Jul 2010 | A1 |
| 20100191326 | Alkhatib | Jul 2010 | A1 |
| 20100249909 | McNamara et al. | Sep 2010 | A1 |
| 20100249910 | McNamara et al. | Sep 2010 | A1 |
| 20100249915 | Zhang | Sep 2010 | A1 |
| 20100256548 | McNamara et al. | Oct 2010 | A1 |
| 20100256753 | McNamara et al. | Oct 2010 | A1 |
| 20100298755 | McNamara et al. | Nov 2010 | A1 |
| 20100324652 | Aurilia | Dec 2010 | A1 |
| 20110022057 | Eigler et al. | Jan 2011 | A1 |
| 20110022157 | Essinger et al. | Jan 2011 | A1 |
| 20110054515 | Bridgeman et al. | Mar 2011 | A1 |
| 20110071623 | Finch et al. | Mar 2011 | A1 |
| 20110071624 | Finch et al. | Mar 2011 | A1 |
| 20110093059 | Fischell et al. | Apr 2011 | A1 |
| 20110152923 | Fox | Jun 2011 | A1 |
| 20110190874 | Celermajer et al. | Aug 2011 | A1 |
| 20110218479 | Rottenberg et al. | Sep 2011 | A1 |
| 20110218480 | Rottenberg et al. | Sep 2011 | A1 |
| 20110218481 | Rottenberg et al. | Sep 2011 | A1 |
| 20110257723 | McNamara | Oct 2011 | A1 |
| 20110264203 | Dwork et al. | Oct 2011 | A1 |
| 20110276086 | Al-Qbandi et al. | Nov 2011 | A1 |
| 20110295182 | Finch et al. | Dec 2011 | A1 |
| 20110295183 | Finch et al. | Dec 2011 | A1 |
| 20110295362 | Finch et al. | Dec 2011 | A1 |
| 20110295366 | Finch et al. | Dec 2011 | A1 |
| 20110306916 | Nitzan et al. | Dec 2011 | A1 |
| 20110319806 | Wardle | Dec 2011 | A1 |
| 20120022507 | Najafi et al. | Jan 2012 | A1 |
| 20120022633 | Olson et al. | Jan 2012 | A1 |
| 20120035590 | Whiting et al. | Feb 2012 | A1 |
| 20120041422 | Whiting et al. | Feb 2012 | A1 |
| 20120046528 | Eigler et al. | Feb 2012 | A1 |
| 20120046739 | Von Oepen et al. | Feb 2012 | A1 |
| 20120053686 | McNamara et al. | Mar 2012 | A1 |
| 20120071918 | Amin et al. | Mar 2012 | A1 |
| 20120130301 | McNamara et al. | May 2012 | A1 |
| 20120165928 | Nitzan et al. | Jun 2012 | A1 |
| 20120179172 | Paul et al. | Jul 2012 | A1 |
| 20120190991 | Bornzin et al. | Jul 2012 | A1 |
| 20120265296 | McNamara et al. | Oct 2012 | A1 |
| 20120271398 | Essinger et al. | Oct 2012 | A1 |
| 20120289882 | McNamara et al. | Nov 2012 | A1 |
| 20120290062 | McNamara et al. | Nov 2012 | A1 |
| 20130030521 | Nitzan et al. | Jan 2013 | A1 |
| 20130046373 | Cartledge et al. | Feb 2013 | A1 |
| 20130138145 | Von Oepen | May 2013 | A1 |
| 20130178783 | McNamara et al. | Jul 2013 | A1 |
| 20130178784 | McNamara et al. | Jul 2013 | A1 |
| 20130184633 | McNamara et al. | Jul 2013 | A1 |
| 20130184634 | McNamara et al. | Jul 2013 | A1 |
| 20130197423 | Keren et al. | Aug 2013 | A1 |
| 20130197547 | Fukuoka et al. | Aug 2013 | A1 |
| 20130197629 | Gainor et al. | Aug 2013 | A1 |
| 20130204175 | Sugimoto | Aug 2013 | A1 |
| 20130231737 | McNamara et al. | Sep 2013 | A1 |
| 20130261531 | Gallagher et al. | Oct 2013 | A1 |
| 20130281988 | Magnin et al. | Oct 2013 | A1 |
| 20130304192 | Chanduszko | Nov 2013 | A1 |
| 20140012181 | Sugimoto et al. | Jan 2014 | A1 |
| 20140012303 | Heipl | Jan 2014 | A1 |
| 20140012368 | Sugimoto et al. | Jan 2014 | A1 |
| 20140012369 | Murry, III et al. | Jan 2014 | A1 |
| 20140067037 | Fargahi | Mar 2014 | A1 |
| 20140094904 | Salahieh et al. | Apr 2014 | A1 |
| 20140128795 | Keren et al. | May 2014 | A1 |
| 20140128796 | Keren et al. | May 2014 | A1 |
| 20140163449 | Rottenberg et al. | Jun 2014 | A1 |
| 20140194971 | McNamara | Jul 2014 | A1 |
| 20140213959 | Nitzan et al. | Jul 2014 | A1 |
| 20140222144 | Eberhardt et al. | Aug 2014 | A1 |
| 20140249621 | Eidenschink | Sep 2014 | A1 |
| 20140257167 | Celermajer | Sep 2014 | A1 |
| 20140275916 | Nabutovsky et al. | Sep 2014 | A1 |
| 20140277045 | Fazio et al. | Sep 2014 | A1 |
| 20140277054 | McNamara et al. | Sep 2014 | A1 |
| 20140303710 | Zhang et al. | Oct 2014 | A1 |
| 20140350565 | Yacoby | Nov 2014 | A1 |
| 20140350658 | Benary et al. | Nov 2014 | A1 |
| 20140350661 | Schaeffer | Nov 2014 | A1 |
| 20140350669 | Gillespie et al. | Nov 2014 | A1 |
| 20140357946 | Golden et al. | Dec 2014 | A1 |
| 20150005810 | Center et al. | Jan 2015 | A1 |
| 20150034217 | Vad | Feb 2015 | A1 |
| 20150039084 | Levi et al. | Feb 2015 | A1 |
| 20150066140 | Quadri et al. | Mar 2015 | A1 |
| 20150073539 | Geiger et al. | Mar 2015 | A1 |
| 20150112383 | Sherman et al. | Apr 2015 | A1 |
| 20150119796 | Finch | Apr 2015 | A1 |
| 20150127093 | Hosmer et al. | May 2015 | A1 |
| 20150142049 | Delgado et al. | May 2015 | A1 |
| 20150148731 | McNamara et al. | May 2015 | A1 |
| 20150148896 | Karapetian et al. | May 2015 | A1 |
| 20150157455 | Hoang et al. | Jun 2015 | A1 |
| 20150173897 | Raanani et al. | Jun 2015 | A1 |
| 20150182334 | Bourang et al. | Jul 2015 | A1 |
| 20150190229 | Seguin | Jul 2015 | A1 |
| 20150196383 | Johnson | Jul 2015 | A1 |
| 20150201998 | Roy et al. | Jul 2015 | A1 |
| 20150209143 | Duffy et al. | Jul 2015 | A1 |
| 20150230924 | Miller et al. | Aug 2015 | A1 |
| 20150238314 | Bortlein et al. | Aug 2015 | A1 |
| 20150245908 | Nitzan et al. | Sep 2015 | A1 |
| 20150272731 | Racchini et al. | Oct 2015 | A1 |
| 20150282790 | Quinn et al. | Oct 2015 | A1 |
| 20150282931 | Brunnett et al. | Oct 2015 | A1 |
| 20150313599 | Johnson et al. | Nov 2015 | A1 |
| 20150359556 | Vardi | Dec 2015 | A1 |
| 20160007924 | Eigler et al. | Jan 2016 | A1 |
| 20160022423 | McNamara et al. | Jan 2016 | A1 |
| 20160022970 | Forcucci et al. | Jan 2016 | A1 |
| 20160073907 | Nabutovsky et al. | Mar 2016 | A1 |
| 20160120550 | McNamara et al. | May 2016 | A1 |
| 20160129260 | Mann et al. | May 2016 | A1 |
| 20160157862 | Hernandez et al. | Jun 2016 | A1 |
| 20160166381 | Sugimoto et al. | Jun 2016 | A1 |
| 20160184561 | McNamara et al. | Jun 2016 | A9 |
| 20160206423 | O'Connor et al. | Jul 2016 | A1 |
| 20160213467 | Backus et al. | Jul 2016 | A1 |
| 20160220360 | Lin et al. | Aug 2016 | A1 |
| 20160220365 | Backus et al. | Aug 2016 | A1 |
| 20160262878 | Backus et al. | Sep 2016 | A1 |
| 20160262879 | Meiri et al. | Sep 2016 | A1 |
| 20160287386 | Alon et al. | Oct 2016 | A1 |
| 20160296325 | Edelman et al. | Oct 2016 | A1 |
| 20160361167 | Tuval et al. | Dec 2016 | A1 |
| 20160361184 | Tabor et al. | Dec 2016 | A1 |
| 20170035435 | Amin et al. | Feb 2017 | A1 |
| 20170056171 | Cooper | Mar 2017 | A1 |
| 20170113026 | Finch | Apr 2017 | A1 |
| 20170128705 | Forcucci et al. | May 2017 | A1 |
| 20170135685 | McNamara et al. | May 2017 | A9 |
| 20170165532 | Khan et al. | Jun 2017 | A1 |
| 20170216025 | Nitzan et al. | Aug 2017 | A1 |
| 20170224323 | Rowe et al. | Aug 2017 | A1 |
| 20170224444 | Viecilli et al. | Aug 2017 | A1 |
| 20170231766 | Hariton et al. | Aug 2017 | A1 |
| 20170273790 | Vettukattil et al. | Sep 2017 | A1 |
| 20170281339 | Levi et al. | Oct 2017 | A1 |
| 20170312486 | Nitzan et al. | Nov 2017 | A1 |
| 20170319823 | Yacoby et al. | Nov 2017 | A1 |
| 20170325956 | Rottenberg et al. | Nov 2017 | A1 |
| 20170348100 | Lane | Dec 2017 | A1 |
| 20180099128 | McNamara et al. | Apr 2018 | A9 |
| 20180104053 | Alkhatib et al. | Apr 2018 | A1 |
| 20180125630 | Hynes et al. | May 2018 | A1 |
| 20180130988 | Nishikawa et al. | May 2018 | A1 |
| 20180243071 | Eigler et al. | Aug 2018 | A1 |
| 20180256865 | Finch et al. | Sep 2018 | A1 |
| 20180263766 | Nitzan et al. | Sep 2018 | A1 |
| 20180280667 | Keren | Oct 2018 | A1 |
| 20180344994 | Karavany et al. | Dec 2018 | A1 |
| 20190000327 | Doan et al. | Jan 2019 | A1 |
| 20190008628 | Eigler et al. | Jan 2019 | A1 |
| 20190015103 | Sharma | Jan 2019 | A1 |
| 20190015188 | Eigler et al. | Jan 2019 | A1 |
| 20190021861 | Finch | Jan 2019 | A1 |
| 20190239754 | Nabutovsky et al. | Aug 2019 | A1 |
| 20190254814 | Nitzan et al. | Aug 2019 | A1 |
| 20190262118 | Eigler et al. | Aug 2019 | A1 |
| 20190328513 | Levi et al. | Oct 2019 | A1 |
| 20190336163 | McNamara et al. | Nov 2019 | A1 |
| 20200060825 | Rottenberg et al. | Feb 2020 | A1 |
| 20200078558 | Yacoby et al. | Mar 2020 | A1 |
| 20200085600 | Schwartz et al. | Mar 2020 | A1 |
| 20200197178 | Vecchio | Jun 2020 | A1 |
| 20200261705 | Nitzan et al. | Aug 2020 | A1 |
| 20200315599 | Nae et al. | Oct 2020 | A1 |
| 20200368505 | Nae et al. | Nov 2020 | A1 |
| 20210052378 | Nitzan et al. | Feb 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 2003291117 | Apr 2009 | AU |
| 2378920 | Feb 2001 | CA |
| 1987777 | Nov 2008 | EP |
| 2238933 | Oct 2010 | EP |
| 2305321 | Apr 2011 | EP |
| 1965842 | Nov 2011 | EP |
| 3400907 | Nov 2018 | EP |
| 2827153 | Jan 2003 | FR |
| WO-9531945 | Nov 1995 | WO |
| WO-9727898 | Aug 1997 | WO |
| WO-9960941 | Dec 1999 | WO |
| WO-0044311 | Aug 2000 | WO |
| WO-0050100 | Aug 2000 | WO |
| WO-0110314 | Feb 2001 | WO |
| WO-0226281 | Apr 2002 | WO |
| WO-02071974 | Sep 2002 | WO |
| WO-02087473 | Nov 2002 | WO |
| WO-03053495 | Jul 2003 | WO |
| WO-2005027752 | Mar 2005 | WO |
| WO-2005074367 | Aug 2005 | WO |
| WO-2006127765 | Nov 2006 | WO |
| WO-2007083288 | Jul 2007 | WO |
| WO-2008055301 | May 2008 | WO |
| WO-2009029261 | Mar 2009 | WO |
| WO-2010128501 | Nov 2010 | WO |
| WO-2010129089 | Nov 2010 | WO |
| WO-2010139771 | Dec 2010 | WO |
| WO-2011062858 | May 2011 | WO |
| WO-2013096965 | Jun 2013 | WO |
| WO-2016178171 | Nov 2016 | WO |
| WO-2017118920 | Jul 2017 | WO |
| WO-2018158747 | Sep 2018 | WO |
| WO-2019015617 | Jan 2019 | WO |
| WO-2019085841 | May 2019 | WO |
| WO-2019109013 | Jun 2019 | WO |
| WO-2019142152 | Jul 2019 | WO |
| WO-2019179447 | Sep 2019 | WO |
| WO-2019218072 | Nov 2019 | WO |
| WO-2020206062 | Oct 2020 | WO |
| WO-2020257530 | Dec 2020 | WO |
| WO-2021050589 | Mar 2021 | WO |
| WO-2021113670 | Jun 2021 | WO |
| WO-2021212011 | Oct 2021 | WO |
| WO-2022046921 | Mar 2022 | WO |
| WO-2022076601 | Apr 2022 | WO |
| Entry |
|---|
| Ando et al., “Left ventricular decompression through a patent foramen ovale in a patient with hypertropic cardiomyopathy: A case report,” Cardiovascular Ultrasound 2: 1-7 (2004). |
| Atrium Advanta V12, Balloon Expandable Covered Stent, Improving Patient Outcomes with an Endovascular Approach, Brochure-8 pages, Getinge (2017). |
| Braunwald, Heart Disease, Chapter 6, p. 186. |
| Bridges, et al., The Society of Thoracic Surgeons Practice Guideline Series: Transmyocardial Laser Revascularization, Ann Thorac Surg., 77:1494-1502 (2004). |
| Bristow et al., Improvement in cardiac myocite function by biological effects of medical therapy: a new concept in the treatment of heart failure, European Heart Journal 16 (Suppl.F): 20-31 (1995). |
| Case et al., “Relief of High Left-Atrial Pressure in Left-Ventricular Failure,” Lancet, pp. 841-842 (Oct. 14, 1964). |
| Coats et al., “Controlled trial of physical training in chronic heart failure: Exercise performance, hemodynamics, ventilation and autonomic function,” Circulation 85:2119-2131 (1992). |
| Partial International Search dated Aug. 17, 2017 in Int'l PCT Patent Appl. Serial No. PCT/IB2017/053188. |
| Davies et al., “Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure,” Circulation 92: 2540-2549 (1995). |
| Ennezat et al., An unusual case of low-flow, low-gradient severe aortic stenosis: Left-to-right shunt due to atrial septal defect, Cardiology 113(2): 146-148 (2009). |
| Ewert et al., “Acute left heart failure after interventional occlusion of an atrial septal defect,” Z Kardiol. 90(5): 362-366 (May 2001). |
| Ewert et al., Masked Left Ventricular Restriction in Elderly Patients With Atrial Septal Defects: A Contraindication for Closure?, Catheterization and Cardiovascular Interventions 52: 177-180 (2001). |
| Extended EP Search Report dated Sep. 19, 2016 in EP Patent Application Serial No. 16170281.6. |
| Extended European Search Report dated Jan. 8, 2015 in EP Patent Appl No. 10772089.8. |
| Geiran et al., “Changes in cardiac dynamics by opening an interventricular shunt in dogs,” J. Surg. Res. 48(1): 6-12 (Jan. 1990). |
| Gelernter-Yaniv et al., “Transcatheter closure of left-to-right interatrial shunts to resolve hypoxemia,” Conginit. Heart Dis. 31(1) 47-53 (Jan. 2008). |
| Gewillig et al., “Creation with a stent of an unrestrictive lasting atrial communication,” Cardio. Young 12(4): 404-407 (2002). |
| International Search Report & Written Opinion dated May 29, 2018 in Int'l PCT Patent Appl. Serial No. PCTIB2018/051355. |
| International Search Report for PCT/IL2005/000131,3 pages (dated Apr. 7, 2008). |
| International Search Report for PCT/IL2010/000354 dated Aug. 25, 2010 (1 pg). |
| Int'l Search Report & Written Opinion dated Feb. 16, 2015 in Int'l PCT Patent Appl. Serial No. PCT/IB2014/001771. |
| Khositseth et al., Transcatheter Amplatzer Device Closure of Atrial Septal Defect and Patent Foramen Ovale in Patients With Presumed Paradoxical Embolism, Mayo Clinic Proc., 79:35-41 (2004). |
| Kramer et al., “Controlled study of captopril in chronic heart failure: A rest and exercise hemodynamic study,” Circulation 67(4): 807-816 (1983). |
| Lai et al., Bidirectional Shunt Through a Residual Atrial Septal Defect After Percutaneous Transvenous Mitral Commissurotomy, Cardiology 83(3): 205-207 (1993). |
| Lemmer et al., “Surgical implications of atrial septal defect complicating aortic balloon valvuloplasty,” Ann Thorac. Surg. 48(2): 295-297 (Aug. 1989). |
| Merriam-Webster “Definition of‘Chamber’,” O-line Dictionary 2004, Abstract. |
| Park, et al., Blade Atrial Septostomy: Collaborative Study, Circulation, 66(2):258-266 (1982). |
| Roven et al., “Effect of Compromising Right Ventricular Function in Left Ventricular Failure by Means of Interatrial and Other Shunts,” American Journal Cardiology, 24:209-219 (1969). |
| Salehian et al., Improvements in Cardiac Form and Function After Transcatheter Closure of Secundum Atrial Septal Defects, Journal of the American College of Cardiology, 45(4):499-504 (2005). |
| Schmitto et al., Chronic heart failure induced by multiple sequential coronary microembolization in sheep, The International Journal of Artificial Organs, 31(4):348-353 (2008). |
| Schubert et al., Left Ventricular Conditioning in the Elderly Patient to Prevent Congestive Heart Failure After Transcatheter Closure of the Atrial Septal Defect, Catheterization and Cardiovascular Interventions,64(3): 333-337 (2005). |
| Stormer et al., Comparative Study of n vitro Flow Characteristics Between a Human Aortic Valve and a Designed Aortic Valve and Six Corresponding Types of Prosthetic Heart Valves, European Surgical Research 8(2): 117-131 (1976). |
| Stumper et al., “Modified technique of stent fenestration of the atrial septum,” Heart 89: 1227-1230 (2003). |
| Trainor et al., Comparative Pathology of an Implantable Left Atrial Pressure Sensor, ASAIO Journal, Clinical Cardiovascular/Cardiopulmonary Bypass, 59(5):486-92 (2013). |
| Zhou et al., Unidirectional Valve Patch for Repair of Cardiac Septal Defects With Pulmonary Hypertension, Annals of Thoracic Surgeons, 60:1245-1249 (1995). |
| Abraham et al., “Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial,” J Card Failure, 22:940 (2016) (Abstract Only). |
| Abraham et al., “Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial,” The Lancet, http://dx.doi.org/10.1016/S0140-6736(15)00723-0 (2015). |
| Abraham et al., “Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial,” The Lancet, DOI:10.1016/S0140-6736(11)60101-3 (2011). |
| Abreu et al., “Doppler ultrasonography of the femoropopliteal segment in patients with venous ulcer,” J Vase Bras., 11(4):277-285 (2012). |
| Adamson et al., “Ongoing Right Ventricular Hemodynamics in Heart Failure Clinical Value of Measurements Derived From an Implantable Monitoring System,” J Am Coll Cardiol., 41(4):565-571 (2003). |
| Adamson et al., “Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction,” Circ Heart Fail., 7:935-944 (2014). |
| Ambrosy et al. “The Global Health and Economic Burden of Hospitalizations for Heart Failure,” J Am Coll Cardiol., 63:1123-1133 (2014). |
| Aminde et al., “Current diagnostic and treatment strategies for Lutembacher syndrome: the pivotal role of echocardiography,” Cardiovasc Diagn Ther., 5(2):122-132 (2015). |
| Anderas E. “Advanced MEMS Pressure Sensors Operating in Fluids,” Digital Comprehensive Summaries of Uppsala Dissertation from the Faculty of Science and Technology 933. Uppsala ISBN 978-91-554-8369-2 (2012). |
| Anderas et al., “Tilted c-axis Thin-Film Bulk Wave Resonant Pressure Sensors with Improved Sensitivity,” IEEE Sensors J., 12(8):2653-2654 (2012). |
| Article 34 Amendments dated May 28, 2013 in Int'l PCT Patent Appl. Serial No. PCT/IB2012/001859. |
| Article 34 Amendments dated Nov. 27, 2012 in Int'l PCT Patent Appl. Serial No. PCT/IL2011/000958. |
| Ataya et al., “A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy,” J. Clin. Med., 5(12):114(2016). |
| Bannan et al., “Characteristics of Adult Patients with Atrial Septal Defects Presenting with Paradoxical Embolism.,” Catheterization and Cardiovascular Interventions, 74:1066-1069 (2009). |
| Baumgartner et al., “ESC Guidelines for the management of grown-up congenital heart disease (new version 2010)—The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC),” Eur Heart J., 31:2915-2957 (2010). |
| Beemath et al., “Pulmonary Embolism as a Cause of Death in Adults Who Died With Heart Failure,” Am J Cardiol., 98:1073-1075 (2006). |
| Benza et al., “Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor,” CHEST, 156(6):1176-1186 (2019). |
| Boehm, et al., “Balloon Atrial Septostomy: History and Technique,” Images Paeditr. Cardiol., 8(1):8-14(2006). |
| Bruch et al., “Fenestrated Occluders for Treatment of ASD in Elderly Patients with Pulmonary Hypertension and/or Right Heart Failure,” J Interven Cardiol., 21(1):44-49 (2008). |
| Burkhoff et al., “Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers,” Am J Physiol Heart Circ Physiol., 289:H501-H512 (2005). |
| Butler et al. “Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials,” JAMA., 312(8):789-790 (2014). |
| Chakko et al., “Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care,” Am J Medicine, 90:353-359 (1991) (Abstract Only). |
| Chang et al., “State-of-the-art and recent developments in micro/nanoscale pressure sensors for smart wearable devices and health monitoring systems,” Nanotechnology and Precision Engineering, 3:43-52 (2020). |
| Chen et al., “Continuous wireless pressure monitoring and mapping with ultra-small passive sensors for health monitoring and critical care,” Nature Communications, 5(1):1-10 (2014). |
| Chen et al., “National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008,” JAMA, 306(15):1669-1678 (2011). |
| Chiche et al., “Prevalence of patent foramen ovale and stroke in pulmonary embolism patients,” Eur Heart J., 34:P1142 (2013) (Abstract Only). |
| Chin et al., “The right ventricle in pulmonary hypertension,” Coron Artery Dis., 16(1):13-18 (2005) (Abstract Only). |
| Chun et al., “Lifetime Analysis of Hospitalizations and Survival of Patients Newly Admitted With Heart Failure,” Circ Heart Fail., 5:414-421 (2012). |
| Ciarka et al., “Atrial Septostomy Decreases Sympathetic Overactivity in Pulmonary Arterial Hypertension,” Chest, 131(6):P1831-1837 (2007) (Abstract Only). |
| Cleland et al., “The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe—Part 1: patient characteristics and diagnosis,” Eur Heart J., 24:442-463 (2003). |
| Clowes et al., “Mechanisms of Arterial Graft Healing—Rapid Transmural Capillary Ingrowth Provides a Source of Intimal Endothelium and Smooth Muscle in Porous PTFE Prostheses,” Am J Pathol., 123:220-230 (1986). |
| Davies et al., “Abnormal left heart function after operation for atrial septal defect,” British Heart Journal, 32:747-753 (1970). |
| Del Trigo et al., “Unidirectional Left-to-Right Interatrial Shunting for Treatment of Patients with Heart Failure with Reduced Ejection Fraction: a Safety and Proof-of-Principle Cohort Study,” Lancet, 387:1290-1297 (2016). |
| Della Lucia et al., “Design, fabrication and characterization of SAW pressure sensors for offshore oil and gas exploration,” Sensors and Actuators A: Physical, 222:322-328 (2015). |
| Drazner et al., “Prognostic Importance of Elevated Jugular Venous Pressure and a Third Heart Sound in Patients with Heart Failure,” N Engl J Med., 345(8):574-81 (2001). |
| Drazner et al., “Relationship between Right and Left-Sided Filling Pressures in 1000 Patients with Advanced Heart Failure,” Heart Lung Transplant, 18:1126-1132 (1999). |
| Drexel, et al., “The Effects of Cold Work and Heat Treatment on the Properties of Nitinol Wire, Proceedings of the International Conference on Shape Memory and Superelastic Technologies, SMST 2006,” Pacific Grove, California, USA (pp. 447-454) May 7-11, 2006. |
| Eigler et al., “Cardiac Unloading with an Implantable Interatrial Shunt in Heart Failure: Serial Observations in an Ovine Model of Ischemic Cardiomyopathy,” Structural Heart, 1:40-48 (2017). |
| Eigler, et al., Implantation and Recovery of Temporary Metallic Stents in Canine Coronary Arteries, JACC, 22(4):1207-1213 (1993). |
| Eshaghian et al., “Relation of Loop Diuretic Dose to Mortality in Advanced Heart Failure,” Am J Cardiol., 97:1759-1764 (2006). |
| Extended European Search Report dated Mar. 29, 2019 in EP Patent Appl. Serial No. EP16789391. |
| Feldman et al., “Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure with Preserved Ejection Fraction (Reduce LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]), A Phase 2, Randomized, Sham-Controlled Trial,” Circulation, 137:364-375 (2018). |
| Ferrari et al., “Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers: results from an international survey,” Eur Respir J., 42:26312 (2013) (Abstract Only). |
| Fonarow et al., “Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure,” J Am Coll Cardiol., 50(8):768-777 (2007). |
| Fonarow et al., “Risk Stratification for in-Hospital Mortality in Acutely Decompensated Heart Failure: Classification and Regression Tree Analysis,” JAMA, 293(5):572-580 (2005). |
| Fonarow, G., “The Treatment Targets in Acute Decompensated Heart Failure,” Rev Cardiovasc Med., 2:(2):S7-S12 (2001). |
| Galie et al., “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension—The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS),” European Heart Journal, 37:67-119 (2016). |
| Galie et al., “Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses,” Eur Heart J., 31:2080-2086 (2010). |
| Galipeau et al., “Surface acoustic wave microsensors and applications,” Smart Materials and Structures, 6(6):658-667 (1997) (Abstract Only). |
| Geva et al., “Atrial septal defects,” Lancet, 383:1921-32 (2014). |
| Gheorghiade et al., “Acute Heart Failure Syndromes, Current State and Framework for Future Research,” Circulation, 112:3958-3968 (2005). |
| Gheorghiade et al., “Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized With Worsening Heart Failure a Randomized Controlled Trial,” JAMA., 291:1963-1971 (2004). |
| Go et al. “Heart Disease and Stroke Statistics—2014 Update—A Report From the American Heart Association,” Circulation, 128:1-267 (2014). |
| Guillevin et al., “Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives,” Eur Respir Rev., 22:535-542 (2013). |
| Guyton et al., “Effect of Elevated Left Atrial Pressure and Decreased Plasma Protein Concentration on the Development of Pulmonary Edema,” Circulation Research, 7:643-657 (1959). |
| Hasenfub, et al., A Transcatheter Intracardiac Shunt Device for Heart Failure with Preserved Ejection Fraction (Reduce LAP-HF): A Multicentre, Open-Label, Single-Arm, Phase 1 Trial, www.thelancet.com, 387:1298-1304 (2016). |
| Hoeper et al., “Definitions and Diagnosis of Pulmonary Hypertension,” J Am Coll Cardiol., 62(5):D42-D50 (2013). |
| Hogg et al., “Heart Failure With Preserved Left Ventricular Systolic Function. Epidemiology, Clinical Characteristics, and Prognosis,” J Am Coll Cardiol., 43(3):317-327 (2004). |
| Howell et al., “Congestive heart failure and outpatient risk of venous thromboembolism: A retrospective, case-control study,” Journal of Clinical Epidemiology, 54:810-816 (2001). |
| Huang et al., “Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses,” Am J Physiol Heart Circ Physiol., 286:H2141-H2150 (2004). |
| Humbert et al., “Pulmonary Arterial Hypertension in France—Results from a National Registry,” Am J Respir Crit Care Med., 173:1023-1030 (2006). |
| International Search Report & Written Opinion dated May 29, 2018 in Int'l PCT Patent Appl. Serial No. PCI/IB2018/051355. |
| International Search Report & Written Opinion dated Feb. 6, 2013 in Int'l PCT Patent Appl. No. PCT/IB2012/001859, 12 pages. |
| International Search Report & Written Opinion dated Feb. 7, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2019/060257. |
| International Search Report & Written Opinion dated May 13, 2019 in Int'l PCT Patent Appl. No. PCT/IB2019/050452. |
| International Search Report & Written Opinion dated Jul. 14, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/053832. |
| International Search Report & Written Opinion dated Jul. 20, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/054699. |
| International Search Report & Written Opinion dated Aug. 12, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/053118. |
| International Search Report & Written Opinion dated Aug. 28, 2012 in Int'l PCT Patent Appl. No. PCT/IL2011/000958. |
| International Search Report & Written Opinion dated Sep. 21, 2020 in Int'l PCT Patent Appl. Serial No. PCT/IB2020/054306. |
| International Search Report & Written Opinion dated Oct. 26, 2007 in Int'l PCT Patent Appl. Serial No. PCT/IB07/50234. |
| Jessup et al. “2009Focused Update: ACC/AHA Guidelines for the Diagnosisand Management of Heart Failure in Adults: A Report of the American College ofCardiology Foundation/American Heart Association Task Force on PracticeGuidelines: Developed in Collaboration With the International Society for Heartand Lung Transplantation,” J. Am. Coll. Cardiol., 53:1343-1382 (2009). |
| Jiang, G., “Design challenges of implantable pressure monitoring system,” Frontiers in Neuroscience, 4(29):1-4 (2010). |
| Kane et al., “Integration of clinical and hemodynamic parameters in the prediction of long-term survival in patients with pulmonary arterial hypertension,” Chest, 139(6):1285-1293 (2011) (Abstract Only). |
| Kaye et al., “Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure,” Journal of Cardiac Failure, 20(3): 212-221 (2014). |
| Kaye et al., “One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction,” Circulation: Heart Failure, 9(12):e003662 (2016). |
| Keogh et al., “Interventional and Surgical Modalitiesof Treatment in Pulmonary Hypertension,” J Am Coll Cardiol., 54:S67-77 (2009). |
| Kretschmar et al., “Shunt Reduction With a Fenestrated Amplatzer Device,” Catheterization and Cardiovascular Interventions, 76:564-571 (2010). |
| Kropelnicki et al., “CMOS-compatible ruggedized high-temperature Lamb wave pressure sensor,” J. Micromech. Microeng., 23:085018 pp. 1-9 (2013). |
| Krumholz et al., “Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and Readmission,” Circ Cardiovasc Qual Outcomes, 2:407-413 (2009). |
| Kulkarni et al., “Lutembacher's syndrome,” J Cardiovasc Did Res., 3(2):179-181 (2012). |
| Kurzyna et al., “Atrial Septostomy in Treatment of End-Stage Right Heart Failure in Patients With Pulmonary Hypertension,” Chest, 131:977-983 (2007). |
| Lammers et al., “Efficacy and Long-Term Patency of Fenerstrated Amplatzer Devices in Children,” Catheter Cardiovasc Interv., 70:578-584 (2007). |
| Lindenfeld et al. “Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline,” J. Cardiac Failure, 16(6):475-539 (2010). |
| Luo, Yi,Selective and Regulated RF Heating of Stent Toward Endohyperthermia Treatment of In-Stent Restenosis, A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Applied Science in the Faculty of Graduate and Postdoctoral Studies (Electrical and Computer Engineering), The University of British Columbia, Vancouver, Dec. 2014. |
| MacDonald et al., “Emboli Enter Penetrating Arteries of Monkey Brain in Relation to Their Size,” Stroke, 26:1247-1251 (1995). |
| Maluli et al., “Atrial Septostomy: A Contemporary Review,” Clin. Cardiol., 38(6):395-400 (2015). |
| Maurer et al., “Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF),” Journal of Cardiac Failure., 21(6): 479-488 (2015). |
| McClean et al., “Noninvasive Calibration of Cardiac Pressure Transducers in Patients With Heart Failure: An Aid to Implantable Hemodynamic Monitoring and Therapeutic Guidance,” J Cardiac Failure, 12(7):568-576 (2006). |
| McLaughlin et al., “Management of Pulmonary Arterial Hypertension,” J Am Coll Cardiol., 65(18):1976-1997 (2015). |
| McLaughlin et al., “Survival in Primary Pulmonary Hypertension—The Impact of Epoprostenol Therapy.,” Circulation, 106:1477-1482 (2002). |
| Mu et al., “Dual mode acoustic wave sensor for precise pressure reading,” Applied Physics Letters, 105:113507-1—113507-5 (2014). |
| Nagaragu et al., “A 400μW Differential FBAR Sensor Interface IC with digital readout,” IEEE., pp. 218-221 (2015). |
| Noordegraaf et al., “The role of the right ventricle in pulmonary arterial hypertension,” Eur Respir Rev., 20(122):243-253 (2011). |
| O'Byrne et al., “The effect of atrial septostomy on the concentration of brain-type natriuretic peptide in patients with idiopathic pulmonary arterial hypertension,” Cardiology in the Young, 17(5):557-559 (2007) (Abstract Only). |
| Oktay et al., “The Emerging Epidemic of Heart Failure with Preserved Ejection Fraction,” Curr Heart Fail Rep., 10(4):1-17 (2013). |
| Owan et al., “Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction,” N Engl J Med., 355:251-259 (2006). |
| Paitazoglou et al., “Title: The AFR-Prelieve Trial: A prospective, non-randomized, pilot study to assess the Atrial Flow Regulator (AFR) in Heart Failure Patients with either preserved or reduced ejection fraction,” EuroIntervention, 28:2539-50 (2019). |
| Park Blade Septostomy Catheter Instructions for Use, Cook Medical, 28 pages, Oct. 2015. |
| Partial Supplemental European Search Report dated Dec. 11, 2018 in EP Patent Appl. Serial No. 16789391.6. |
| Peters et al., “Self-fabricated fenestrated Amplatzer occluders for transcatheter closure of atrial septal defect in patients with left ventricular restriction: midterm results,” Clin Res Cardiol., 95:88-92 (2006). |
| Ponikowski et al., “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC),” Eur Heart J., doi:10.1093/eurheartj/ehw128 (2016). |
| Potkay, J. A., “Long term, implantable blood pressure monitoring systems,” Biomed Microdevices, 10:379-392 (2008). |
| Pretorious et al., “An Implantable Left Atrial Pressure Sensor Lead Designed for Percutaneous Extraction Using Standard Techniques,” PACE, 00:1-8 (2013). |
| Rajeshkumar et al., “Atrial septostomy with a predefined diameter using a novel occlutech atrial flow regulator improves symptoms and cardiac index in patients with severe pulmonary arterial hypertension,” Catheter Cardiovasc Interv., 1-9 (2017). |
| Rich et al., “Atrial Septostomy as Palliative Therapy for Refractory Primary Pulmonary Hypertension,” Am J Cardiol., 51:1560-1561 (1983). |
| Ritzema et al., “Direct Left Atrial Pressure Monitoring in Ambulatory Heart Failure Patients—Initial Experience With a New Permanent Implantable Device,” Circulation, 116:2952-2959 (2007). |
| Ritzema et al., “Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure,” Circulation, 121:1086-1095 (2010). |
| Roberts et al., “Integrated microscopy techniques for comprehensive pathology evaluation of an implantable left atrial pressure sensor,” J Histotechnology, 36(1):17-24 (2013). |
| Rodes-Cabau et al., “Interatrial Shunting for Heart Failure Early and Late Results From the First-in-Human Experience With the V-Wave System,” J Am Coll Cardiol Intv., 11:2300-2310.doi:10.1016/j.cin.2018.07.001 (2018). |
| Rosenquist et al., Atrial Septal Thickness and Area in Normal Heart Specimens and in Those With Ostium Secundum Atrial Septal Defects, J. Clin. Ultrasound, 7:345-348 (1979). |
| Ross et al., “Interatrial Communication and Left Atrial Hypertension—A Cause of Continuous Murmur,” Circulation, 28:853-860 (1963). |
| Rossignol, et al., Left-to-Right Atrial Shunting: New Hope for Heart Failure, www.thelancet.com, 387:1253-1255 (2016). |
| Sandoval et al., “Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension,” Eur Respir J., 38:1343-1348 (2011). |
| Sandoval et al., “Graded Balloon Dilation Atrial Septostomy in Severe Primary Pulmonary Hypertension—A Therapeutic Alternative for Patients Nonresponsive to Vasodilator Treatment,” JACC, 32(2):297-304 (1998). |
| Schiff et al., “Decompensated heart failure: symptoms, patterns of onset, and contributing factors,” Am J. Med., 114(8):625-630 (2003) (Abstract Only). |
| Schneider et al., “Fate of a Modified Fenestration of Atrial Septal Occluder Device after Transcatheter Closure of Atrial Septal Defects in Elderly Patients,” J Interven Cardiol., 24:485-490 (2011). |
| Scholl et al., “Surface Acoustic Wave Devices for Sensor Applications,” Phys Status Solidi Appl Res., 185(1):47-58 (2001) (Abstract Only). |
| Setoguchi et al., “Repeated hospitalizations predict mortality in the community population with heart failure,” Am Heart J., 154:260-266 (2007). |
| Shah et al., “Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction—5-Year Outcomes,” J Am Coll Cardiol., https://doi.org/10.1016/j.jacc.2017.08.074 (2017). |
| Shah et al., “One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF I) Trial—A Randomized Clinical Trial,” JAMA Cardiol. doi:10.1001/jamacardio.2018.2936 (2018). |
| Sitbon et al., “Selexipag for the Treatment of Pulmonary Arterial Hypertension.,” N Engl J Med., 373(26):2522-2533 (2015). |
| Sitbon et al., “Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience,” Eur Respir Rev., 26:160055:1-14 (2017). |
| Steimle et al., “Sustained Hemodynamic Efficacy of Therapy Tailored to Reduce Filling Pressures in Survivors With Advanced Heart Failure,” Circulation, 96:1165-1172 (1997). |
| Stevenson et al., “The Limited Reliability of Physical Signs for Estimating Hemodynamics in Chronic Heart Failure,” JAMA, 261(6):884-888 (1989) (Abstract Only). |
| Su et al., “A film bulk acoustic resonator pressure sensor based on lateral field excitation,” International Journal of DistributedSensor Networks, 14(11):1-8 (2018). |
| Supplementary European Search Report dated Nov. 13, 2009 in EP Patent Appl. Serial No. 05703174.2. |
| Thenappan et al., “Evolving Epidemiology of Pulmonary Arterial Hypertension,” Am J Resp Critical Care Med., 186:707-709 (2012). |
| Tomai et al., “Acute Left Ventricular Failure After Transcatheter Closure of a Secundum Atrial Septal Defect in a Patient With Coronary Artery Disease: A Critical Reappraisal,” Catheterization and Cardiovascular Interventions, 55:97-99 (2002). |
| Torbicki et al., “Atrial Septostomy,” The Right Heart, 305-316 (2014). |
| Troost et al., “A Modified Technique of Stent Fenestration of the Interatrial Septum Improves Patients With Pulmonary Hypertension,” Catheterization and Cardiovascular Interventions, 73:173179 (2009). |
| Troughton et al., “Direct Left Atrial Pressure Monitoring in Severe Heart Failure: Long-Term Sensor Performance,” J. of Cardiovasc. Trans. Res., 4:3-13 (2011). |
| Vank-Noordegraaf et al., “Right Heart Adaptation to Pulmonary Arterial Hypertension—Physiology and Pathobiology,” J Am Coll Cardiol., 62(25):D22-33 (2013). |
| Verel et al., “Comparison of left atrial pressure and wedge pulmonary capillary pressure—Pressure gradients between left atrium and left ventricle,” British Heart J., 32:99-102 (1970). |
| Viaene et al., “Pulmonary oedema after percutaneous ASD-closure,” Acta Cardiol., 65(2):257-260 (2010). |
| Wang et al., “A Low Temperature Drifting Acoustic Wave Pressure Sensor with an Integrated Vacuum Cavity for Absolute Pressure Sensing,” Sensors, 20(1788):1-13 (2020). |
| Warnes et al., “ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease—A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease),” JACC, 52(23):e143-e263 (2008). |
| Webb et al., “Atrial Septal Defects in the Adult Recent Progress and Overview,” Circulation, 114:1645-1653 (2006). |
| Wiedemann, H.R., “Earliest description by Johann Friedrich Meckel, Senior (1750) of what is known today as Lutembacher syndrome (1916),” Am J Med Genet., 53(1):59-64 (1994) (Abstract Only). |
| Written Opinion of the International Searching Authority dated Apr. 7, 2008 in Int'l PCT Patent Appl. Serial No. PCT/IL05/00131. |
| Yantchev et al., “Thin Film Lamb Wave Resonators in Frequency Control and Sensing Applications: A Review,” Journal of Micromechanics and Microengineering, 23(4):043001 (2013). |
| Zhang et al., “Acute left ventricular failure after transcatheter closure of a secundum atrial septal defect in a patient with hypertrophic cardiomyopathy,” Chin Med J., 124(4):618-621 (2011). |
| Zhang et al., “Film bulk acoustic resonator-based high-performance pressure sensor integrated with temperature control system,” J Micromech Microeng., 27(4):1-10 (2017). |
| Borlaug, et al., Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure, Circulation (Mar. 2022). |
| Flachskampf, et al., Influence of Orifice Geometry and Flow Rate on Effective Valve Area: An In Vitro Study, Journal of the American College of Cardiology, 15(5):1173-1180 (Apr. 1990). |
| International Search Report & Written Opinion dated Nov. 7, 2016 in Int'l PCT Patent Appl. Serial No. PCT/IB2016/052561. |
| International Search Report & Written Opinion dated Feb. 9, 2022 in Int'l PCT Patent Appl. Serial No. PCT/IB2021/060473 (2010). |
| International Search Report & Written Opinion dated May 17, 2022 in Int'l PCT Patent Appl. Serial No. PCT/IB2022/051177. |
| International Search Report & Written Opinion dated Jul. 23, 2021 in Int'l PCT Patent Appl. Serial No. PCT/IB2021/053594. |
| Kaye, et al., One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure with Preserved Ejection Fraction, Circulation: Heart Failure, 9(12):e003662 (Dec. 2016). |
| Shah, et al., Atrial Shunt Device for Heart Failure With Preserved and Mildly Reduced Ejection Fraction (Reduce LAP-HF II): A Randomised, Multicentre, Blinded, Sham-Controlled Trial, The Lancet, 399(10330):1130-1140 (Mar. 2022). |
| Number | Date | Country | |
|---|---|---|---|
| 20200315599 A1 | Oct 2020 | US |
